Er is verder onderzoek nodig om de bevindingen van de cohort study te valideren (bevestigen).
Journal of Clinical Microbiology; Bron https://jcm.asm.org/
Publicatie 21 april 2021
Study - 'Diagnostic performance of the novel BioPlex Lyme serological assays in European patients with Lyme disease' by M.E. (Ewoud) Baarsma, Jeanine Ursinus, Hans L. Zaaijer, Herman Kuiper, Joppe W. Hovius; Bron https://jcm.asm.org/content/early/2021/ ... M.03205-20
Abstract
Objectives
Serodiagnosis of Lyme borreliosis (LB) comes with several drawbacks, among which limited sensitivity in early disease. This study assesses the sensitivity and specificity of the novel BioPlex 2200 Lyme IgG & Lyme IgM assays. It also assesses potential improvements to the assays through ROC-analysis.
Methods
The BioPlex assays were performed on sera of 158 Dutch patients with physician-confirmed LB (both early localized and disseminated), 800 healthy blood donors from the Netherlands and 90 cross-reactive controls. The BioPlex assays were compared with two commercial enzyme immunoassays (Euroimmun/C6-ELISA) and one immunoblot (recomLine).
Conclusions
The BioPlex 2200 Lyme IgG & Lyme IgM assays are promising tools for the serodiagnosis of early LB, with the potential to be used as a standalone test. Further research is necessary to validate the findings of this discovery cohort.